Document:

Exhibit 10.2

 

SECURITIES PURCHASE AGREEMENT

DOCUMENT SPA-12072017

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of December __, 2017, between ActiveCare, Inc., a Delaware corporation
(the “Issuer”) and ______________________ (the “Investor”) (referred to collectively herein
as the “Parties”).

 

WHEREAS, the Issuer
intends to conduct a private placement of its securities to raise net proceeds to the Issuer of at least $5,000,000 (the “Private
Placement”);

 

WHEREAS, the Issuer
anticipates closing the Private Placement prior to May 5, 2018;

 

WHEREAS, the Issuer
is seeking financing as a bridge until completion of the Private Placement;

 

WHEREAS, this Agreement
is one of a series of Securities Purchase Agreements with investors to provide bridge financing of at least $600,000 in the aggregate
(the “Bridge Financing”); and

 

WHEREAS, the Issuer
desires to sell and the Investor desires to purchase a Promissory Note, issued by the Issuer to the Investor, in the form of Exhibit
A attached hereto (the “Note”), a Warrant to purchase shares of the Issuer’s common stock for a period
of five (5) years from the date hereof, issued by the Issuer to the Investor, in the form of Exhibit B attached hereto (the “Warrant”),
and shares of common stock of the Issuer (the “Origination Shares,” and together with the Note and the Warrant,
the “Securities”) as set forth below.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained in this Agreement, the Issuer and the Investor agree as follows:

 

ARTICLE I PURCHASE AND SALE

 

1.1 Purchase and
Sale. Upon the terms and subject to the conditions set forth herein, the Issuer agrees to sell, and the Investor agrees to
purchase the Note, the Warrant, and the Origination Shares.

 

1.1.1 On
or before the Closing, the Investor shall deliver to Lucosky Brookman, counsel to the Issuer, to hold in escrow until Closing:

 

(a) The Note
duly executed by the Investor;

 

(b) The Warrant
duly executed by the Investor;

 

(c) A wire
transfer of immediately available funds in the amount of US $______ (the “Purchase Price”) to Lucosky Brookman’s
Attorney Trust Account.

 

1.1.2 On
or before the Closing, the Issuer shall deliver or cause to be delivered to Lucosky Brookman, counsel to the Issuer, to hold in
escrow until Closing:

 

(a) The Note
duly executed by the Issuer;

 

(b) The Warrant
duly executed by the Issuer;

 

(c) An executed
agreement terminating the consulting agreement with David Derrick;

 

(d) The resignation
of Jeffery Peterson as Chief Executive Officer of the Issuer;

 

(e) The resignation
of all members of the Board of Directors other than Jeffrey Peterson;

 

(f) An executed
employment agreement with Mark Rosenblum in the form attached hereto as Exhibit C retaining Mr. Rosenblum to serve as the Chief
Executive Officer of the Issuer effective upon closing of the Bridge Financing;

 

    	 	1	 

     

    

 

(g) Duly
adopted resolutions of the Board of Directors of the Issuer appointing Mr. Rosenblum as Chairman of the Board of Directors and
Isaac Onn as a member of the Board of Directors, effective upon closing of the Bridge Financing; and

 

(h) Wire
instructions for a US bank account in the name of the Issuer from which only Mr. Rosenblum has the authority to distribute funds
(the “New Bank Account”).

 

1.1.3 On
or before the Closing, the Issuer and the Investor shall deliver all other documents or agreements related to this transaction.

 

1.2 Closing.
The closing of the transactions contemplated by this Agreement shall occur simultaneously with the other Bridge Financing closings,
and which shall occur only upon completion of both of the following: (i) Lucosky Brookman’s receipt of all items required to be
delivered prior to Closing as set forth in Section 1.1; and (ii) Lucosky Brookman’s receipt of an aggregate of at least $600,000
of Bridge Financing for the Issuer, including the $___________ being provided by the Investor under this Agreement, on terms substantially
identical to the terms being provided to the Investor under this Agreement. If the Closing does not occur on or before December
11, 2017, this Agreement shall be cancelled and Lucosky Brookman shall return the Purchase Price to the Investor. At the Closing,
Lucosky Brookman shall deliver the funds from the Bridge Financing to the New Bank Account and Lucosky Brookman shall deliver the
Note and the Warrant to the Investor.

 

1.3 Origination
Shares. The Issuer shall deliver the Origination Shares to the Investor as follows:

 

1.3.1 Origination
Share Pricing. On the fifth (5th) trading day after the pricing of the Private Placement, but in no event later than
no later than six months from the date hereof, the Issuer shall deliver to the Investor such number of duly and validly issued,
fully paid and non-assessable Origination Shares as equals 30% of the Purchase Price paid by the Investor under this Agreement
(the “Origination Dollar Amount”) divided by the lowest of (i) $3.00 (subject to adjustment for stock splits),
(ii) 80% of the common stock offering price in the Private Placement, (iii) 80% of the unit price offering price of the Private
Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement. It is the Issuer’s
and the Investor’s expectation that the issuance date of the Origination Shares dates back to the effective date of this
Agreement for purposes of Rule 144 under the Securities Act of 1933, as amended (“Rule 144”).

 

1.3.2 Origination
Share Pricing Reset. In the event that the Private Placement is not completed within six months from the date hereof, so long as
the Investor owns any of the Origination Shares at the time of a subsequent public offering where the pricing terms from paragraph
1.3.1 above would result in a lower Origination Share pricing, the Origination Shares pricing shall be subject to a reset based
on the same pricing terms as described in paragraph 1.3.1 above (such that the Origination Shares issuance price would be reduced
and the number of Origination Shares issued would be increased to equal the Origination Dollar Amount). It is the Issuer’s
and the Investor’s expectation that the issuance date of any repriced Origination Shares dates back to the effective date
of this Agreement for purposes of Rule 144.

 

1.3.3 Origination
Share Beneficial Ownership Limitation. Unless otherwise agreed by both Parties, at no time will the Issuer issue to the Investor
such number of Origination Shares that would result in the Investor owning more than 9.99% of the number of shares of common stock
outstanding of the Issuer immediately after giving effect to the issuance of the Origination Shares (the “Beneficial Ownership
Limitation”). In the event that the number of Origination Shares deliverable to the Investor pursuant to Section 1.3.1
or 1.3.2 above would cause the Investor to exceed the Beneficial Ownership Limitation, the Issuer shall deliver to the Investor
such lesser number of Origination Shares the Investor requests that would result in the Investor owning less than the Beneficial
Ownership Limitation and the Issuer shall deliver to the Investor the remaining number of Origination Shares at such time as the
Investor notifies the Issuer that delivery of such remaining Origination Shares would not cause the Investor to exceed the Beneficial
Ownership Limitation.”

 

ARTICLE II BRIDGE LOAN

 

2.1 Recitals.
The Issuer represents and warrants to the Investor that the first five recitals set forth above are true as of the date of this
Agreement.

 

    	 	2	 

     

    

 

2.2. Note Conversion
into Private Placement. At the closing of the Private Placement the Note shall automatically convert into a subscription into
the Private Placement in an amount equal to 125% of the Note balance, subject to the following conditions: (i) 90% of the debt
listed on the attached Schedule A must convert into shares of common stock of the Issuer at the Private Placement price per share,
including, without limitation, all debt (and preferred stock) held by insiders and affiliates of the Issuer (as indicated by the
blue highlighting on Schedule A); (ii) the Private Placement raises at least $5,000,000 of net new money for the Issuer, not including
any conversions of the Bridge Financing or conversions of the debt on Schedule A; (iii) no commission is paid to a placement agent
in connection with the conversion and subscription into the Private Placement of the Note, the other Bridge Financing, or the conversion
of the debt on Schedule A; (iv) the Warrant and the Origination Shares being issued under this Agreement will not be cancelled
or converted into the Private Placement; and (v) the Private Placement closes on or before May 5, 2018.

 

ARTICLE III MISCELLANEOUS

 

3.1 Successors and
Assigns. This Agreement may not be assigned by the Issuer. The Investor may assign any or all of its rights under this Agreement
and agreements related to this transaction. The terms and conditions of this Agreement shall inure to the benefit of, and be binding
upon, the respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended
to confer upon any party, other than the parties hereto or their respective successors, any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

3.2 Reservation
of Shares. RESERVED.

 

3.3 Rule 144 Tacking
Back and Registration Rights. Whenever the Note or Warrant or any other document related to this transaction provides that
a conversion amount, make-whole amount, penalty, fee, liquidated damage, or any other amount or shares (a “Tack Back Amount”)
tacks back to the original date of the Note, Warrant, or document for purposes of Rule 144 or otherwise, in the event that such
Tack Back Amount was registered or carried registration rights, then that Tack Back Amount shall have the same registration status
or registration rights as were in effect immediately prior to the event that gave rise to such Tack Back Amount tacking back. For
example, if the Investor converts a portion of the Note and receives registered shares and the Investor later rescinds that conversion,
the conversion amount would be returned to the principal balance of the Note and upon any future conversion of the Note the amount
converted would be convertible into shares registered on that registration statement.

 

3.4 Terms of Future
Financings. Until such time as the closing of the Private Placement, upon any issuance by the Issuer or any of its subsidiaries
of any security with any term more favorable to the holder of such security or with a term in favor of the holder of such security
that was not similarly provided to the Investor in the Note or the warrants, such term, at the Investor’s option, shall become
a part of the transaction documents with the Investor. The types of terms contained in another security that may be more favorable
to the holder of such security include, but are not limited to, terms addressing conversion rights, conversion discounts, conversion
lookback periods, interest rates, original issue discounts, stock issuance or sale price pursuant to a stock purchase or stock
issuance, and warrant coverage.

 

In addition, until such time as the closing
of the Private Placement, if the Issuer shall issue or sell Common Stock, or grant any option to purchase, or sell or grant any
right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition)
any Common Stock (including pursuant to the terms of any outstanding securities issued prior to the issuance of this security (including,
but not limited to, warrants, convertible notes, or other agreements)) or any security entitling the holder thereof (including
pursuant to sales, grants, conversions, warrant exercises or other issuances to the Investor as a result of these Transaction Documents,
prior transaction documents, or future transaction documents) to acquire Common Stock, including, without limitation, any debt,
preferred stock, right, option, warrant or other instrument that is convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive Common Stock (a “Common Stock Equivalent”) at an effective price per
share less than that of the Investor, then simultaneously with the consummation of each dilutive issuance the price for the Investor
shall be reduced (and only reduced) and consequently the number of Shares issuable to the Investor shall be increased (and only
increased). Such adjustment shall be made to the Note, such Warrants, or Origination Shares whenever such Common Stock or Common
Stock Equivalents are issued.

 

    	 	3	 

     

    

 

The Issuer shall notify the Investor of
such additional or more favorable term, including the applicable issuance price, or applicable reset price, exchange price, conversion
price, exercise price and other pricing terms, and, at any time while the Note or any warrant is outstanding, the Investor may
request of the Issuer and/or its transfer agent (and they will provide) a schedule of all issuances since the date of this Agreement
of shares of common stock or of securities entitling the holder thereof to acquire shares of common stock, including, without limitation,
any debt, preferred stock, right, option, warrant or other instrument that is convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, shares of common stock of the Issuer.

 

3.5 One Year Prohibition
on Issuances of Securities. For a period of one year after the closing of the Private Placement, the Issuer shall not issue
or sell Common Stock, or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue
(or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock (including pursuant to the
terms of any outstanding securities issued prior to the closing of the Public Offering (including, but not limited to, warrants,
convertible notes, or other agreements)) or any security entitling the holder thereof to acquire Common Stock, including, without
limitation, any debt, preferred stock, right, option, warrant or other instrument that is convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive Common Stock (a “Common Stock Equivalent”) at an effective
price per share less than the greatest of (i) the Exercise Price then in effect of any Warrant issued to the Investor, (ii) the
common stock offering price in the Public Offering, (iii) the unit price offering price in the Public Offering (if applicable),
and (iv) the exercise price of any warrants issued in the Public Offering.

 

3.6 Governing Law,
Legal Proceedings, and Arbitration. This Agreement will be governed by, construed and
enforced in accordance with the substantive laws of the State of Nevada, without regard to the conflict of laws principles thereof.
The parties hereby warrant and represent that the selection of Nevada law as governing under this Agreement (i) has a reasonable
nexus to each of the Parties and to the transactions contemplated by the Agreement; and (ii) does not offend any public policy
of Nevada, Florida, or of any other state, federal, or other jurisdiction.

 

Any
action brought by either party against the other arising out of or related to this Agreement, or any other agreements between the
parties, shall be commenced only in the state or federal courts of general jurisdiction located in Miami-Dade County, in the State
of Florida, except that all such disputes between the parties shall be subject to alternative dispute resolution through binding
arbitration at the Investor’s sole discretion and election (regardless of which party initiates the legal proceedings).
The parties agree that, in connection with any such arbitration proceeding, each shall submit or file any claim which would constitute
a compulsory counterclaim within the same proceeding as the claim to which it relates. Any such claim that is not submitted or
filed in such proceeding shall be waived and such party will forever be barred from asserting such a claim. Both parties and the
individuals signing this Note agree to submit to the jurisdiction of such courts or to such arbitration panel, as the case may
be.

 

If the Investor elects alternative dispute
resolution by arbitration, the arbitration proceedings shall be conducted in Miami-Dade County and administered by the American
Arbitration Association in accordance with its Commercial Arbitration Rules and Mediation Procedures in effect on the date of this
Agreement, except as modified by this Agreement. The Investor’s demand for arbitration shall be made in writing, delivered
to the other party, and filed with the American Arbitration Association. The American Arbitration Association must receive the
demand for arbitration prior to the date when the institution of legal or equitable proceedings would be barred by the applicable
statute of limitations, unless legal or equitable proceedings between the parties have already commenced, and the receipt by the
American Arbitration Association of a written demand for arbitration also shall constitute the institution of legal or equitable
proceedings for statute of limitations purposes. The parties shall be entitled to limited discovery at the discretion of the arbitrator(s)
who may, but are not required to, allow depositions. The parties acknowledge that the arbitrators’ subpoena power is not
subject to geographic limitations. The arbitrator(s) shall have the right to award individual relief which he or she deems proper
under the evidence presented and applicable law and consistent with the parties’ rights to, and limitations on, damages and
other relief as expressly set forth in this Agreement. The award and decision of the arbitrator(s) shall be conclusive and binding
on all parties, and judgment upon the award may be entered in any court of competent jurisdiction. The Investor reserves the right,
but shall have no obligation, to advance the Issuer’s share of the costs, fees and expenses of any arbitration proceeding,
including any arbitrator fees, in order for such arbitration proceeding to take place, and by doing so will not be deemed to have
waived or relinquished its right to seek the recovery of those amounts from the arbitrator, who shall provide for such relief in
the final award, in addition to the costs, fees, and expenses that are otherwise recoverable. The foregoing agreement to arbitrate
shall be specifically enforceable under applicable law in any court having jurisdiction thereof.

 

    	 	4	 

     

    

 

3.7 Right to Specific
Performance and Injunctive Relief. Nothing herein shall limit the Investor’s right to pursue any remedies available to
it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. In this regard,
the Issuer hereby agrees that the Investor will be entitled to obtain specific performance and/or injunctive relief with respect
to the Issuer’s failure to timely deliver shares of common stock as required pursuant to the terms of the Note or the Warrant
or the Issuer’s obligations regarding the reservation of shares and its transfer agent, including the use, termination, replacement
or resignation of the transfer agent and the obligation to deliver an irrevocable instruction and share reservation letter with
any subsequent transfer agent. The Issuer agrees that, in such event, all requirements for specific performance and/or preliminary
and permanent injunctive relief will be satisfied, including that the Investor would suffer irreparable harm for which there would
be no adequate legal remedy. The Issuer further agrees that it will not object to a court or arbitrator granting or ordering specific
performance or preliminary and/or permanent injunctive relief in the event the Investor demonstrates that the Issuer has failed
to comply with any obligation herein. Such a grant or order may require the Issuer to immediately issue shares to the Investor,
and/or require the Issuer to immediately satisfy its obligations regarding the reservation of shares and its transfer agent, including
the use, termination, replacement or resignation of the transfer agent and the obligation to deliver an irrevocable instruction
and share reservation letter with any subsequent transfer agent. The Issuer further expressly waives any right to any bond in connection
with any temporary or preliminary injunction.

 

3.8 Due Diligence.
RESERVED.

 

3.9 Delivery of
Process by Investor to Issuer. In the event of any action or proceeding by the Investor against the Issuer, and only by Investor
against the Issuer, service of copies of summons and/or complaint and/or any other process which may be served in any such action
or proceeding may be made by Investor via U.S. Mail, overnight delivery service such as FedEx or UPS, email, fax, or process server,
or by mailing or otherwise delivering a copy of such process to the Issuer at its last known address or to its last known attorney
as set forth in its most recent SEC filing.

 

3.10 Opinion of
Counsel. RESERVED

 

3.11 Notices.
Any notice required or permitted hereunder must be in writing and either be personally served, sent by facsimile or email transmission,
or sent by overnight courier. Notices will be deemed effectively delivered at the time of transmission if by facsimile or email,
and if by overnight courier the business day after such notice is deposited with the courier service for delivery.

 

3.12 Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Delivery of this Agreement may be effected by email.

 

3.13 Entire Agreement.
This Agreement and the other Transaction Documents constitute the entire agreement between the Parties with respect to the subject
matter hereof and thereof and supersedes all prior agreements and understandings, both oral and written, between the Parties with
respect to the subject matter hereof and thereof. The “Transaction Documents” means this Agreement, the Note,
the Warrant and all schedules and exhibits related thereto.

 

3.14 Expenses.
The Issuer and the Investor shall pay all of their own costs and expenses incurred with respect to the negotiation, execution,
delivery and performance of this Agreement. In the event any attorney is employed by either party to this Agreement with respect
to legal or equitable action, arbitration or other proceeding brought by such party for the enforcement of this Agreement or because
of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions of this Agreement, the prevailing
party in such proceeding will be entitled to recover from the other party reasonable attorneys’ fees and other costs and
expenses incurred, in addition to any other relief to which the prevailing party may be entitled.

 

3.15 No Public Announcement.
Except as required by securities law, no public announcement may be made regarding this Agreement, the Note, the Warrant, or the
Purchase Price without written permission by both the Issuer and the Investor.

 

3.16 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction.

 

*      *      *

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of this __th day of December, 2017.

 

	 	ISSUER:
	 	 
	 	ACTIVECARE, INC.
	 	 	 
	 	By: 	 
	 	 	Jeffrey S. Peterson
	 	 	Chief Executive Officer
	 	 	 
	 	INVESTOR:
	 	 	 
	 	 
	 	By: 	 

 

I, Jeffrey S. Peterson, personally guarantee
that, as set forth in Section 3.2 above, in the event of a change in the Issuer’s transfer agent, the Issuer will provide
the Investor, within five business days following termination, resignation or replacement of the Issuer’s transfer agent
or any subsequent transfer agent, irrevocable instruction letters, executed by the Issuer and the new transfer agent, providing
rights to the Investor identical to the rights provided to the Investor in the irrevocable instruction letters between the Issuer,
the Investor, and American Stock Transfer & Trust Company. This personal guarantee is limited to and applies only to the terms
of this paragraph.

 

	 	 
	Jeffrey S. Peterson	 

 

[Securities Purchase Agreement Signature
Page]

 

    	 	6	 

     

    

 

SCHEDULE A

 

(See attached)

 

    	 	7	 

     

    

 

Exhibit A

 

Note 

 

(see attached)

 

    	 	8	 

     

    

 

Exhibit B

 

Warrant 

 

(See attached)

 

    	 	9	 

     

    

 

Exhibit C

 

Employment Agreement 

 

(See attached)

 

    	 	10Exhibit 10.3

 

	ACAR
	 

 

CONVERTIBLE
NOTE

 

FOR
VALUE RECEIVED, ActiveCare, Inc., a Delaware corporation (the “Issuer” of this Security) with at least 239,000,000
common shares issued and outstanding, issues this Security and promises to pay to __________________., a Cayman Islands company,
or its Assignees (the “Investor”) the Principal Sum along with the Interest Rate and any other fees according to the
terms herein. This Note will become effective only upon execution by both parties and delivery of the first payment of Consideration
by the Investor (the “Effective Date”).

 

The
Principal Sum is $_______ (______________) plus accrued and unpaid interest and any other fees. The Consideration is $_________
(________) payable by wire (there exists a $________ original issue discount (the “OID”)). The Investor shall pay
$__________of Consideration upon closing of this Note as the Purchase Price under the Securities Purchase Agreement Document SPA-12072017
of even date herewith between the Issuer and the Investor. Any term not otherwise defined herein shall have the meaning given
such term in the Securities Purchase Agreement.

 

1.       Interest
and Repayment. No interest shall accrue on this Note. The Maturity Date is six months after the Effective Date and is the
date upon which the Principal Sum of this Note, as well as any unpaid interest and other fees, shall be due and payable. The Investor
may extend any Maturity Date in its sole discretion in increments of up to three months at any time before or after any Maturity
Date. The Issuer may repay this Note at any time on or before its Maturity Date.

 

2.       Note
Conversion into Private Placement. At the closing of the Private Placement the Note shall automatically convert into a subscription
into the Private Placement in an amount equal to 125% of the Note balance, subject to the following conditions: (i) 90% of the
debt listed on Schedule A of the Securities Purchase Agreement must convert into shares of common stock of the Issuer at the Private
Placement price per share, including, without limitation, all debt (and preferred stock) held by insiders and affiliates of the
Issuer (as indicated by the blue highlighting on Schedule A); (ii) the Private Placement raises at least $5,000,000 of net new
money for the Issuer, not including any conversions of the Bridge Financing or conversions of the debt on Schedule A; (iii) no
commission is paid to a placement agent in connection with the conversion and subscription into the Private Placement of the Note,
the other Bridge Financing, or the conversion of the debt on Schedule A; (iv) the Warrant and the Origination Shares being issued
under the Securities Purchase Agreement will not be cancelled or converted into the Private Placement; and (v) the Private Placement
closes on or before May 5, 2018.

 

3.       Conversion
upon Default on Repayment. In the event the Issuer fails to repay the balance due under this Note on its Maturity Date, the
Investor has the right, at any time, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued
interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Issuer as per this conversion
formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The
Conversion Price is the lesser of $3.00 (subject to adjustment for stock splits) or 60% of the lowest trade price in the 25 trading
days previous to the conversion (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will
apply; and if the shares are ineligible for deposit into the DTC system and only eligible for Xclearing deposit an additional
5% discount shall apply; in the case of both an additional cumulative 15% discount shall apply). Unless otherwise agreed in writing
by both parties, at no time will the Investor convert any amount of the Note into common stock that would result in the Investor
owning more than 9.99% of the common stock outstanding. Conversion notices may be delivered to the Issuer by method of the Investor’s
choice (including but not limited to email, facsimile, mail, overnight courier, or personal delivery), and all conversions shall
be cashless and not require further payment from the Investor. If no objection is delivered from the Issuer to the Investor regarding
any variable or calculation of the conversion notice within 24 hours of delivery of the conversion notice, the Issuer shall have
been thereafter deemed to have irrevocably confirmed and irrevocably ratified such notice of conversion and waived any objection
thereto. The Issuer shall deliver the shares from any conversion to the Investor (in any name directed by the Investor) within
3 (three) business days of conversion notice delivery. The Investor, at any time prior to selling all of the shares from a conversion,
may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares
and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Issuer
(under the Investor’s and the Issuer’s expectations that any returned conversion amounts will tack back to the original
date of the Note).

 

4.       Conversion
Upon Issuance of a Variable Security. If, at any time this Note is outstanding, the Issuer issues a Variable Security, then
in such event the Investor shall have the right to convert all or any portion of the outstanding balance of this Note into shares
of the Issuer’s common stock on the same terms as granted in any applicable Variable Security issued by the Issuer (including,
for the avoidance of doubt, conversion price, conversion discount, conversion lookback period, method and timing of conversion
share delivery, etc.). A Variable Security is any security issued by the Issuer that (i) has or may have conversion rights of
any kind, contingent, conditional or otherwise in which the number of shares that may be issued pursuant to such conversion right
varies with the market price of the common stock; (ii) is or may become convertible into common stock (including without limitation
convertible debt, warrants or convertible preferred stock), with a conversion price that varies with the market price of the common
stock, even if such security only becomes convertible following an event of default, the passage of time, or another trigger event
or condition; or (iii) was issued or may be issued in the future in exchange for or in connection with any contract or instrument,
whether convertible or not, where the number of shares of common stock issued or to be issued is based upon or related in any
way to the market price of the common stock, including, but not limited to, common stock issued in connection with a Section 3(a)(9)
exchange, a Section 3(a)(10) settlement, or any other similar settlement or exchange.

 

5.       Reservation
of Shares. The Issuer will reserve for the Investor from its authorized and unissued Common Stock a number of shares of not
less than five times the number of shares necessary to provide for the issuance of Common Stock upon the full conversion of this
Note.

 

     

    

    

 

6.       Terms
of Future Financings. Until such time as the closing of the Private Placement, upon any issuance by the Issuer of any security
with any term more favorable to the holder of such security or with a term in favor of the holder of such security that was not
similarly provided to the Investor in this Note, such term, at the Investor’s option, shall become a part of the transaction
documents with the Investor. The types of terms contained in another security that may be more favorable to the holder of such
security include, but are not limited to, terms addressing conversion rights, conversion discounts, conversion lookback periods,
interest rates, original issue discounts, and warrant coverage.

 

In
addition, until such time as the closing of the Private Placement, if the Issuer shall issue or sell Common Stock, or grant any
option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant
or any option to purchase or other disposition) any Common Stock (including pursuant to the terms of any outstanding securities
issued prior to the issuance of this security (including, but not limited to, warrants, convertible notes, or other agreements))
or any security entitling the holder thereof (including pursuant to sales, grants, conversions, warrant exercises or other issuances
to the Investor as a result of these Transaction Documents (as defined below), prior transaction documents, or future transaction
documents) to acquire Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
instrument that is convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common
Stock (a “Common Stock Equivalent”) at an effective price per share less than the Conversion Price, then simultaneously
with the consummation of each dilutive issuance the Conversion Price for the Investor shall be reduced (and only reduced) and
consequently the number of Shares issuable to the Investor shall be increased (and only increased). Such adjustment shall be made
to the Conversion Price whenever such Common Stock or Common Stock Equivalents are issued.

 

The
Issuer shall notify the Investor of such additional or more favorable term, including the applicable issuance price, or applicable
reset price, exchange price, conversion price, exercise price and other pricing terms, and, at any time while this Note is outstanding,
the Investor may request of the Issuer and/or its transfer agent (and they will provide) a schedule of all issuances since the
Effective Date of this Note of shares of common stock or of securities entitling the holder thereof to acquire shares of common
stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of common stock of the Issuer.

 

7.       Default.
Each of the following are an event of default under this Note: (i) the Issuer shall fail to pay any principal under the Note when
due and payable (or payable by conversion) thereunder; or (ii) the Issuer shall fail to pay any interest or any other amount under
the Note when due and payable (or payable by conversion) thereunder; or (iii) the Issuer shall breach or fail to honor any other
term of this Note, any term under any other document related to this Note, or any term of any of the other Transaction Documents;
or (iv) the Issuer shall become insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they
become due, subject to applicable grace periods, if any; or (v) the Issuer shall make a general assignment for the benefit of
creditors; or (vi) the Issuer shall file a petition for relief under any bankruptcy, insolvency or similar law (domestic or foreign);
or (vii) an involuntary proceeding shall be commenced or filed against the Issuer.

 

8.       Remedies.
For each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion),
a fee of $2,000 per day will be assessed for each day after the third business day (inclusive of the day of the conversion) until
share delivery is made; and such fee will be added to the Principal Sum of the Note (under the Investor’s and the Issuer’s
expectations that any penalty amounts will tack back to the original date of the Note). The parties agree that the fee shall be
applied to the balance of the Note and shall tack back to the Effective Date of the Note for purposes of Rule 144. The parties
acknowledge and agree that upon an event of default, Investor’s damages would be uncertain and difficult (if not impossible)
to accurately estimate because of the parties’ inability to predict future interest rates and future share prices, Investor’s
increased risk, and the uncertainty of the availability of a suitable substitute investment opportunity for Investor, among other
reasons. Accordingly, any fees, charges, and default interest due under this Note or any other Transaction Document between the
parties are intended by the parties to be, and shall be deemed, liquidated damages. The parties agree that such liquidated damages
are a reasonable estimate of Investor’s actual damages and not a penalty, and shall not be deemed in any way to limit any
other right or remedy Investor may have hereunder, at law or in equity. The parties acknowledge and agree that under the circumstances
existing at the time this Note is entered into, such liquidated damages are fair and reasonable and are not penalties. All fees,
charges, and default interest provided for in this Note and the Transaction Documents are agreed to by the parties to be based
upon the obligations and the risks assumed by the parties as of the Effective Date and are consistent with investments of this
type. The liquidated damages provisions shall not limit or preclude a party from pursuing any other remedy available at law or
in equity; provided, however, that the liquidated damages are intended to be in lieu of actual damages.

 

9.       Acceleration.
In the event of any default, the outstanding principal amount of this Note, plus accrued but unpaid interest, liquidated damages,
fees and other amounts owing in respect thereof through the date of acceleration (the “Note Balance”), shall become,
at the Investor’s election, immediately due and payable in cash at the Mandatory Default Amount. The Mandatory Default Amount
means the Investor’s choice of (this choice may be made at any time without presentment, demand, or notice of any kind):
(i) the Note Balance divided by the Conversion Price on the date of the default multiplied by the closing price on the date of
the default; or (ii) the Note Balance divided by the Conversion Price on the date the Mandatory Default Amount is either (a) demanded
or (b) paid in full, whichever has a lower Conversion Price, multiplied by the closing price on the date the Mandatory Default
Amount is either (a) demanded or (b) paid in full, whichever has a higher closing price; or (iii) 150% of the Note Balance. In
connection with such acceleration described herein, the Investor need not provide, and the Issuer hereby waives, any presentment,
demand, protest or other notice of any kind, and the Investor may immediately and without expiration of any grace period enforce
any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration
may be rescinded and annulled by the Investor at any time prior to payment hereunder and the Investor shall have all rights as
a holder of the note until such time, if any, as the Investor receives full payment pursuant to this Section 9. No such rescission
or annulment shall affect any subsequent event of default or impair any right consequent thereon.

 

    	 	2	 

    

    

 

10.       Right
to Specific Performance and Injunctive Relief. Nothing herein shall limit the Investor’s right to pursue any other remedies
available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.
In this regard, the Issuer hereby agrees that the Investor will be entitled to obtain specific performance and/or injunctive relief
with respect to the Issuer’s failure to timely deliver shares of Common Stock upon conversion of the Note as required pursuant
to the terms hereof or the Issuer’s obligations regarding the reservation of shares and its transfer agent, including the
use, termination, replacement or resignation of the transfer agent and the obligation to deliver an irrevocable instruction and
share reservation letter with any subsequent transfer agent. The Issuer agrees that, in such event, all requirements for specific
performance and/or preliminary and permanent injunctive relief will be satisfied, including that the Investor would suffer irreparable
harm for which there would be no adequate legal remedy. The Issuer further agrees that it will not object to a court or arbitrator
granting or ordering specific performance or preliminary and/or permanent injunctive relief in the event the Investor demonstrates
that the Issuer has failed to comply with any obligation herein. Such a grant or order may require the Issuer to immediately issue
shares to the Investor pursuant to a Conversion Notice and/or require the Issuer to immediately satisfy its obligations regarding
the reservation of shares and its transfer agent, including the use, termination, replacement or resignation of the Issuer’s
transfer agent and the obligation to deliver an irrevocable instruction and share reservation letter with any subsequent transfer
agent. The Issuer further expressly waives any right to any bond in connection with any temporary or preliminary injunction.

 

11.       No
Shorting. The Investor agrees that so long as this Note from the Issuer to the Investor remains outstanding, the Investor
will not enter into or effect “short sales” of the Common Stock or hedging transaction which establishes a net short
position with respect to the Common Stock of the Issuer. The Issuer acknowledges and agrees that upon delivery of a conversion
notice by the Investor, the Investor immediately owns the shares of Common Stock described in the conversion notice and any sale
of those shares issuable under such conversion notice would not be considered short sales.

 

12.       Assignability.
The Issuer may not assign this Note. This Note will be binding upon the Issuer and its successors and will inure to the benefit
of the Investor and its successors and assigns and may be assigned by the Investor to anyone without the Issuer’s approval.

 

13.       Governing
Law, Legal Proceedings, and Arbitration. This Note will be governed by, construed and
enforced in accordance with the substantive laws of the State of Nevada (including any rights to specific relief provided for
under Nevada statutes), without regard to the conflict of laws principles thereof. The parties hereby warrant and represent that
the selection of Nevada law as governing under this Note (i) has a reasonable nexus to each of the Parties and to the transactions
contemplated by the Note; and (ii) does not offend any public policy of Nevada, Florida, or of any other state, federal, or other
jurisdiction.

 

Any
action brought by either party against the other arising out of or related to this Note, or any other agreements between the parties,
shall be commenced only in the state or federal courts of general jurisdiction located in Miami-Dade County, in the State of Florida,
except that all such disputes between the parties shall be subject to alternative dispute resolution through binding arbitration
at the Investor’s sole discretion and election (regardless of which party initiates the legal proceedings). The
parties agree that, in connection with any such arbitration proceeding, each shall submit or file any claim which would constitute
a compulsory counterclaim within the same proceeding as the claim to which it relates. Any such claim that is not submitted or
filed in such proceeding shall be waived and such party will forever be barred from asserting such a claim. Both parties and the
individuals signing this Note agree to submit to the jurisdiction of such courts or to such arbitration panel, as the case may
be.

 

If
the Investor elects alternative dispute resolution by arbitration, the arbitration proceedings shall be conducted in Miami-Dade
County and administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules and Mediation
Procedures in effect on the Effective Date of this Note, except as modified by this agreement. The Investor’s election to
arbitrate shall be made in writing, delivered to the other party, and filed with the American Arbitration Association. The American
Arbitration Association must receive the demand for arbitration prior to the date when the institution of legal or equitable proceedings
would be barred by the applicable statute of limitations, unless legal or equitable proceedings between the parties have already
commenced, and the receipt by the American Arbitration Association of a written demand for arbitration also shall constitute the
institution of legal or equitable proceedings for statute of limitations purposes. The parties shall be entitled to limited discovery
at the discretion of the arbitrator(s) who may, but are not required to, allow depositions. The parties acknowledge that the arbitrators’
subpoena power is not subject to geographic limitations. The arbitrator(s) shall have the right to award individual relief which
he or she deems proper under the evidence presented and applicable law and consistent with the parties’ rights to, and limitations
on, damages and other relief as expressly set forth in this Note. The award and decision of the arbitrator(s) shall be conclusive
and binding on all parties, and judgment upon the award may be entered in any court of competent jurisdiction. The Investor reserves
the right, but shall have no obligation, to advance the Issuer’s share of the costs, fees and expenses of any arbitration
proceeding, including any arbitrator fees, in order for such arbitration proceeding to take place, and by doing so will not be
deemed to have waived or relinquished its right to seek the recovery of those amounts from the arbitrator, who shall provide for
such relief in the final award, in addition to the costs, fees, and expenses that are otherwise recoverable. The foregoing agreement
to arbitrate shall be specifically enforceable under applicable law in any court having jurisdiction thereof.

 

    	 	3	 

    

    

 

14.       Delivery
of Process by the Investor to the Issuer. In the event of any action or proceeding by the Investor against the Issuer, and
only by the Investor against the Issuer, service of copies of summons and/or complaint and/or any other process which may be served
in any such action or proceeding may be made by the Investor via U.S. Mail, overnight delivery service such as FedEx or UPS, email,
fax, or process server, or by mailing or otherwise delivering a copy of such process to the Issuer at its last known attorney
as set forth in its most recent SEC filing.

 

15.       Attorney
Fees. If any attorney is employed by either party with regard to any legal or equitable action, arbitration or other proceeding
brought by such party for enforcement of this Note or because of an alleged dispute, breach, default or misrepresentation in connection
with any of the provisions of this Note, the prevailing party will be entitled to recover from the other party reasonable attorneys'
fees and other costs and expenses incurred, in addition to any other relief to which the prevailing party may be entitled.

 

16.       Opinion
of Counsel. RESERVED

 

17.       Notices.
Any notice required or permitted hereunder (including Conversion Notices and demands for arbitration) must be in writing and either
personally served, sent by facsimile or email transmission, or sent by overnight courier. Notices will be deemed effectively delivered
at the time of transmission if by facsimile or email, and if by overnight courier the business day after such notice is deposited
with the courier service for delivery.

 

*       *       *

 

	Issuer:	 	Investor:
	 	 	 
	 	 	 
	Jeffrey S. Peterson	 	 
	ActiveCare, Inc.	 	 
	Chief Executive Officer	 	 
	 	 	 
	Date:  	                         	 	Date: 	                         

 

 

[Convertible
Note Signature Page]

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]